Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced the launch of a Single Inhaler Triple Therapy AIRZ-FF - a combination of two bronchodilators, Glycopyrronium & Formoterol and the inhalation corticosteroid Fluticasone propionate, for Chronic Obstructive Pulmonary Disease (COPD).
source https://www.pharmatutor.org/pharma-news/2020/glenmark-introduces-advance-inhaler-therapy-for-copd-in-india
No comments:
Post a Comment